Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report

Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents

“…Of the 213 patients, 174 (82%) were treated according to protocols of the EICNHL, NHL-BFM SG, AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica), UKCCSG (United Kingdom Children's Cancer SG), SFOP (Société Française d'Oncologie Pédiatrique), EORTC (European Organisation for Research and Treatment of Cancer), COG (Children's Oncology Group), and JPLSG (Japanese Pediatric Leukemia/Lymphoma SG). [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] The remaining 39 patients (18%) received CHOP±ritux-imab, COP±rituximab, rituximab only, or miscellaneous treatments. The survey asked for information about dose reductions, suspension of chemotherapy elements or single drugs, and individualized therapy approaches.…”

A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections

“…Scientists have been trying to find the most effective combination between rituximab and different chemotherapy regimens (Dotan et al, 2010;Hohloch et al, 2011;Räty et al, 2012;Haioun et al, 2009;Intragumtornchai et al, 2006;Jermann et al, 2004;Flinn et al, 2014;Lenz et al, 2005;Romaguera et al, 2010;Hauptrock and Hess, 2008;Watanabe et al, 2011;Sousou and Friedberg, 2010;Lefrère et al, 2013;Van et al, 2010;Cunningham et al, 2013;Fowler, 2011;Wang et al, 2013;Goldman et al, 2012;Federico et al, 2013;Hiraga et al, 2009;Ysebaert et al, 2010). In 2006, Cvetković and Perry (2006) systematically reviewed the effectiveness of rituximab combination therapy in literature.…”

Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

“…It is also expressed in >98% of childhood, adolescent, and adult mature B-cell NHLs and therefore is an attractive cancer therapeutic target (6,8,9). Rituximab, a chimeric anti-CD20 antibody, has been used successfully in the treatment of childhood and adolescent mature B-NHL as well as in adults with diffuse large B-cell lymphoma and Burkitt lymphoma (9)(10)(11). However, CD20 could also be used as a target for genetically engineered immune cell-based therapies.…”